| Liz-beth Porter, MD | |
|
Unm Hospital Psychiatry, 2211 Lomas Blvd Ne, Albuquerque, NM 87131-0001 | |
| (505) 272-6225 | |
| Not Available |
| Full Name | Liz-beth Porter |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | Unm Hospital Psychiatry, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013056019 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 98-365 (New Mexico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Liz-beth Porter, MD 2211 Lomas Blvd Ne, Msc 084770, Albuquerque, NM 87131-0001 Ph: (505) 272-6225 | Liz-beth Porter, MD Unm Hospital Psychiatry, 2211 Lomas Blvd Ne, Albuquerque, NM 87131-0001 Ph: (505) 272-6225 |
News Archive
An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston.
Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, including many chemotherapies.
In addition to known antiviral agents such as antibodies and interferons, people also seem to have a similar immune system to that previously identified in plants. This is the result of research carried out by Esther Schnettler at Wageningen University.
A decision support system, in form of a checklist with 20 risk- and need factors, complements clinical evaluation of boys between the ages of six and twelve with behavioural problems, according to new research from Karolinska Institutet.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 8 days ago
Melissa A Merhege, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 500 Walter St Ne Ste 213, Albuquerque, NM 87102 Phone: 505-727-7177 Fax: 505-727-3778 | |
Dr. Anju C Jaiswal, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Children Psychiatric Hospital, 1001 Yale Blvd., Albuquerque, NM 87131 Phone: 505-272-2890 | |
George Edwin Davis, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1002 Idlewilde Ln Se, Albuquerque, NM 87108 Phone: 505-270-7479 | |
Shannon Stromberg, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Unm Psychiatric Ctr, 2600 Marble Ne, Albuquerque, NM 87131 Phone: 505-272-2800 Fax: 505-272-8692 | |
Mr. Ronald Lee Romanik, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7520 Montgomery Blvd Ne, Suite D12, Albuquerque, NM 87109 Phone: 505-323-6969 Fax: 505-323-9696 | |
Dr. Justin F Beatty, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Msc 09 5030 1 University Of New Mexico, Albuquerque, NM 87131 Phone: 505-272-2223 |